Endocrine Practice

Papers
(The H4-Index of Endocrine Practice is 25. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Abstract #1161252: Efficacy and Safety of Tandem Control IQ without User-Initiated Boluses in Adults with Uncontrolled Type 1 Diabetes676
Abstract #1169579: Achievement of HbA1c <6.5% with ≥5% Weight Loss and Without Hypoglycemia in Patients with Type 2 Diabetes Treatment with Tirzepatide: a Post Hoc Analysis of the SURPASS-1 to -5 S321
Abstract #1184116: Predictors of Type 2 Diabetes (T2D) Remission using Digital Twin Technology Based on Artificial Intelligence (AI) and Internet of Things (IoT) Technologies238
Abstract #1184564: A 59-year-old man with type 2 diabetes mellitus with severe neuropsychiatric manifestations due to COVID-19 infection82
Abstract #1160606: Quality Improvement project for effective evaluation and management of Osteoporosis in patients admitted with fragility hip fractures53
Abstract #1592635: Diabetic Emergencies Among Patients With Diabetes Mellitus Who Participated in Hajj, 201950
Abstract #1175512: A Case of McCune Albright Syndrome with Multiple Associated Endocrinopathies49
Abstract #1165370: Unique Case of an Adult Patient with Neurofibromatosis Type 1 with Noonan Syndrome (NFNS) Features and Idiopathic Hypoparathyroidism Complicated by Recurrent Episodes of Hypo- and H45
Abstract #1597635: Optimizing Diabetes Management in LADA: Examining the Effect of Routine Antibody Testing, Correct Diagnosis, and Customized Medication Regimens on HbA1c Control: A Case Series Study44
Abstract #1595981: Changes in Fibroblast Growth Factor-23 and the Klotho Protein Axis in Diabetic Nephropathy41
Abstract #1604642: Positive Impact of Mobile Health Intervention for Patients With T2DM38
AACE2021-A-1097: Clinical and Biochemical Outcomes of Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors in Type 2 Diabetes Mellitus Patients as a Fourth Oral Anti Diabetic Medicine.37
Abstract #1082277: Urinary Albumin Creatinine Ratio Had No Significant Association With Retinopathy in Individuals With Type 1 Diabetes Mellitus37
AACE2021-A-1029: Identifying and Addressing the Determinants That Affect Successful Control of Diabetes Mellitus Type II35
Abstract #1399545: Calcification of Left Atrial Appendage in Autosomal Recessive Hypophosphatemic Rickets Type 2 (ENPP1 Mutation)34
Abstract #1325612: A Novel Methylation Disorder Resulting in Profound Growth Failure Associated With a Mutation in FBXO2232
Abstract #1325308: Alkaline Phosphatase Measurement in Oman: A National Survey and the First Report From MENA Region32
Abstract #1180224: Relapsed hyperprolactinemia with no evidence of pituitary tumor in a woman with a history of pituitary microadenoma30
Abstract #1168064: Surgical Management of Giant Prolactinomas29
Abstract #1609126: Erdheim–Chester Syndrome: A Rare Cause of Diabetes Insipidus and Hypogonadotropic Hypogonadism: Case Report28
Abstract #1182311: A Rare Case of Hyponatremia due to Cerebral Salt Wasting after Transsphenoidal Pituitary Surgery27
Abstract #1319994: Hyperglycemia of Hospital In-Patients With Diabetes: Prevalence, Complications, Comorbidities, and Mortality Rate at SQUH27
Abstract #1404780: Implementing a Screening Protocol for Endocrinopathies in Patients with Secondary Hemochromatosis due to Sickle Cell Anemia26
Abstract #1395490: New Onset of Type 1 Diabetes After Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination26
AACE2021-A-1041: Medullary Thyroid Cancer: An Experience from a Tertiary Care Hospital of a Developing Country25
#1690706 Multi-Faceted Approach in a Residents-Run QI Project To Improve Documentation of Obesity in a Resident Continuity Clinic- A part of a National Level Project25
Abstract #1408177: Spinal Muscle Atrophy Presenting with Non-Diabetic Ketoacidosis25
Table of contents25
Abstract #1413680: Post-Bariatric Hypoglycemia (PBH) Refractory to Conventional Therapies: The Combined Effect of Very High Doses of Glucagon-Like Receptor Agonist (GLP1-RA) and a Low Dose of Sodium-G25
0.1026291847229